pH-Responsive Drug Delivery Nanoplatforms as Smart Carriers of Unsymmetrical Bisacridines for Targeted Cancer Therapy - Publication - Bridge of Knowledge

Search

pH-Responsive Drug Delivery Nanoplatforms as Smart Carriers of Unsymmetrical Bisacridines for Targeted Cancer Therapy

Abstract

Selective therapy and controlled drug release at an intracellular level remain key challenges for effective cancer treatment. Here, we employed folic acid (FA) as a self-navigating molecule in nanoconjugates containing quantum dots (QDs) and β-cyclodextrin (β-CD) for the delivery of antitumor unsymmetrical bisacridine compound (C-2028) to lung and prostate cancers as well as normal cells. The bisacridine derivative can form the inclusion complex with β-cyclodextrin molecule, due to the presence of a planar fragment in its structure. The stability of such a complex is pH-dependent. The drug release profile at different pH values and the mechanism of C-2028 release from QDs-β-CD-FA nanoconjugates were investigated. Next, the intracellular fate of compounds and their influence on lysosomal content in the cells were also studied. Confocal Laser Scanning Microscopy studies proved that all investigated compounds were delivered to acidic organelles, the pH of which promoted an increased release of C-2028 from its nanoconjugates. Since the pH in normal cells is higher than in cancer cells, the release of C-2028 from its nanoconjugates is decreased in these cells. Additionally, we obtained the concentration profiles of C-2028 in the selected cells treated with unbound C-2028 or nanoconjugate by the HPLC analysis.

Citations

  • 8

    CrossRef

  • 0

    Web of Science

  • 9

    Scopus

Authors (9)

Keywords

Details

Category:
Articles
Type:
artykuły w czasopismach
Published in:
Pharmaceutics no. 15,
ISSN: 1999-4923
Language:
English
Publication year:
2023
Bibliographic description:
Pilch J., Potęga A., Kowalczyk A., Kasprzak A., Kowalik P., Bujak P., Paluszkiewicz E., Augustin E., Nowicka A. M.: pH-Responsive Drug Delivery Nanoplatforms as Smart Carriers of Unsymmetrical Bisacridines for Targeted Cancer Therapy// Pharmaceutics -Vol. 15,iss. 1 (2023), s.201-
DOI:
Digital Object Identifier (open in new tab) 10.3390/pharmaceutics15010201
Sources of funding:
Verified by:
Gdańsk University of Technology

seen 132 times

Recommended for you

Meta Tags